Capsid Engineering

Capsid engineering modifies the protein shell structure of viral vectors to enhance transduction efficiency, expand tissue tropism, or reduce immunogenicity in gene therapy applications. These engineered capsids incorporate amino acid substitutions, domain insertions, or chemical conjugations that alter surface properties, receptor binding kinetics, and cellular uptake mechanisms. Advanced approaches employ directed evolution, computational protein design, and high-throughput screening to identify variants with improved therapeutic profiles. Rational design strategies balance transduction efficiency against manufacturing feasibility and regulatory acceptance.

Clinical translation of engineered capsids demonstrates improved biodistribution and reduced off-target engagement in early-phase studies. Manufacturing scale-up requires validation of consistency between engineered and wild-type production processes. Quality attributes including capsid integrity, particle homogeneity, and transgene packaging efficiency demand rigorous analytical characterisation. As gene therapy platforms mature, capsid engineering continues advancing to enable targeted delivery, minimise innate immune activation, and improve therapeutic outcomes across diverse organ systems and disease indications.